Recombinant Mouse MCL1 Protein, His (Fc)-Avi-tagged

• Cat.No.: MCL1-5408M
• Product Overview: Recombinant Mouse MCL1 with His (Fc)-Avi tag was expressed and purified

Specification

• Source: HEK293
• Species: Mouse
• Tag: His&Fc&Avi
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Purity: ≥85% by SDS-PAGE
• Stability: Stable for at least 6 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.
• Storage: For long term storage, aliquot and store at -20 to -80 centigrade. Avoid repeated freezing and thawing cycles.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: Mcl1 myeloid cell leukemia sequence 1 [ Mus musculus ]
• Official Symbol: MCL1
• Gene ID: 17210
• mRNA Refseq: NM_008562.3
• Protein Refseq: NP_032588.1
• UniProt ID: P97287

Reviews

06/20/2022

Another advantage of using MCL1 protein in trials is its potential as a therapeutic agent.

01/16/2022

The manufacturer's support and expertise further enhance the utility of MCL1 in my experimental work, ensuring reliable and high-quality results.

03/23/2016

This collaborative partnership greatly contributes to the success of my research projects and facilitates meaningful contributions to the scientific community.

Q&As

Can targeting MCL1 have implications beyond cancer therapy?

Yes, MCL1 modulation may have therapeutic implications in other diseases, such as neurodegenerative disorders, where apoptosis is a contributing factor.

Are there any diagnostic tools or biomarkers that can assess MCL1 expression in cancer patients?

Immunohistochemistry and molecular assays can be used to measure MCL1 expression levels, providing insights into the prognosis and potential treatment strategies.

How does the understanding of MCL1 function contribute to personalized medicine in cancer treatment?

Understanding MCL1 expression allows for the identification of patients who may benefit from targeted therapies, contributing to personalized treatment strategies.

Are there any ongoing clinical trials exploring MCL1 inhibitors as a therapeutic approach?

Yes, there are several clinical trials investigating the use of MCL1 inhibitors in different cancer types to assess their safety and efficacy.

How does the MCL1 protein interact with other proteins in the Bcl-2 family?

MCL1 interacts with pro-apoptotic and anti-apoptotic proteins in the Bcl-2 family, influencing the balance between cell survival and death.